Soleno rated as new Buy at Goldman Sachs on Vykat XR potential

[The New York Stock Exchange on the Wall street sign]
Dmitry Vinogradov

Soleno Therapeutics (SLNO) has been initiated with Buy at Goldman Sachs citing strong fundamentals and blockbuster potential for its lead asset, Vykat XR, in treating Prader-Willi syndrome.

After decades without effective therapy for this rare genetic disorder, Goldman sees Vykat XR becoming a foundational treatment, capitalizing on its rapid uptake in the U.S. market.

The research firm’s bullish stance rests on the combination of strong early launch execution, a clear competitive edge, and diversified long-term growth drivers, supporting their conviction that SLNO can deliver significant shareholder value over the coming years.

Goldman Sachs has set a price target of $125 for the company.

MORE ON SOLENO THERAPEUTICS

* Soleno Therapeutics: Patient Death Unrelated To Vykat, But Safety Concerns May Undermine Launch [https://seekingalpha.com/article/4823806-soleno-therapeutics-patient-death-unrelated-to-vykat-but-safety-concerns-may-undermine-launch]
* Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4819840-soleno-therapeutics-inc-slno-presents-at-wells-fargo-20th-annual-healthcare-conference-2025]
* Soleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4819342-soleno-therapeutics-inc-slno-presents-at-cantor-global-healthcare-conference-2025-transcript]
* Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps [https://seekingalpha.com/news/4498312-soleno-jumps-acadia-trial-setback]
* Soleno drops on death of patient treated with Vykat XR [https://seekingalpha.com/news/4493802-soleno-drops-as-patient-vykat-xr-dies]